ATNM Earnings
Latest Revenue35.0M
Latest Net Income27.9M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.89 | 35.0M | 27.9M | — | +504.5% |
| Q1 2026 | -$0.18 | 0 | -5522000 | — | +64.7% |
| Q4 2025 | -$0.19 | 0 | -5940000 | — | +9.5% |
| Q3 2025 | -$0.16 | 90.0K | -5131000 | — | +56.8% |
| Q2 2025 | -$0.22 | 0 | -6878000 | — | +42.1% |
| Q1 2025 | -$0.51 | 0 | -15938000 | — | -64.5% |
| Q4 2024 | -$0.21 | 0 | -6652000 | -100.0% | +38.2% |
| Q3 2024 | -$0.37 | 0 | -11568000 | — | +24.5% |
| Q2 2024 | -$0.38 | 0 | -11353000 | — | — |
| Q1 2024 | -$0.31 | 0 | -8670000 | — | — |
| Q4 2023 | -$0.34 | 81.0K | -9324000 | — | — |
| Q3 2023 | -$0.49 | 0 | -13276000 | — | — |
Actinium Pharmaceuticals (ATNM) — Earnings